Revista Cubana de Medicina
On-line version ISSN 1561-302X
SORIANO GARCIA, Jorge L et al. Cyclophosphamide and Methrotexate as a Metronome-chemotherapy used in patients with progressing metastatic breast cancer. Rev cubana med [online]. 2009, vol.48, n.2, pp. 0-0. ISSN 1561-302X.
Introduction: Continuous use of low doses of cytotoxic agents during lengthy periods has shown to be an alternative to treat metastatic breast cancer (MBC), an opening in face of a resistance of known and beneficial drugs in quality of life. Methods: From April, 2002 and December, 2005, a total of 28 patients was assessed with a progressing MBC, Eastern Cooperative Oncology Group (ECOG)= 2, previously treated with, or at least, a chemotherapy line for metastatic disease, and the respective informed consent from patients. We administered: 2.5 mg/b.i.d. of oral Methrotexate during two days, and 50 mg/quotid of Cyclophosphamide during 5 days weekly. We analyzed survival rate by Kaplan-Meier method. Results: We found a mean age of 56 years (36-74), and 13 patients with more than a metastatic site. There was an objective response (RC + RP) in 14 patients, EE en 8, and progression in 6. Average time to obtain a response was of 2.8 months (CI 1.9-3.5), and average length response (in respondents), 7.9 months (IC 3.7-16.2). The metastatic sites with a higher response rate were: skin/soft parts, and liver, and the more observed ones were: anemia and 2-degree leukopenia in 11 patients, 3 degree hepatic toxicity in one patient, and 5 degree in 5 of them; 3 degree nausea in 3 patients, and 2 degree en 6 of them. Conclusions: Metronome-chemotherapy is a very useful therapeutical option in MBC by its benefits, advantages of oral pathway, a scarce toxicity and a low cost.
Keywords : Metastatic breast cancer; metronome-chemotherapy..